A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.

Phase 1

• Conditions: Chronic HCV Hepatitis C

• Registration Number: NCT01164384
• Lead Sponsor: University of Zurich

Brief Summary

Erstes Safety Trial mit Baminercept in chronischen HCV Patienten. Untersuchung des potentiell antiviralen, antiinflammatorischen Effekts sowie Modulation der hepatischen Gen-Expression.

10 Patienten, open label, 10 Wochen Therapie. Sequentielles Enrollement der ersten 4 Patienten.

* Trial with medicinal product

Detailed Description

Not available

Study Timeline

• Status Verified: 2010-07
• Study First Submitted: 2010-07-08
• Study First Submitted QC: 2010-07-15
• Last Update Submitted: 2010-07-15
• Study First Posted: 2010-07-16
• Last Update Posted: 2010-07-16
• Study Start: 2010-10
• Study Completion: 2013-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Sicherheit